Focus on filgotinib and cystic fibrosis

18:00 EDT 28 Jul 2016 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
First half-year financial results: Revenues €48.8 M, an increase of €11.9 M compared to H1 2015 Operating loss €24.3 M, an improvement of € 11.3 M compared to H1 2015 Cash on 30 June 2016 of €968.5 M Ruling for reduced tax rate...

Other Sources for this Article


More From BioPortfolio on "Focus on filgotinib and cystic fibrosis"

Quick Search


Relevant Topics

Cystic Fibrosis
Affecting over 8,500 people in the UK, Cystic Fibrosis (CF) is one of the UK's most common life-threatening inherited diseases. Around half of the CF population can expect to live over 38 years, although improvements in treatments mean a baby born ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...